Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
Biol Psychiatry. 2024 Apr 1;95(7):611-628. doi: 10.1016/j.biopsych.2023.07.019. Epub 2023 Aug 9.
Understanding the interactions between the gut microbiome and psychotropic medications (psycho-pharmacomicrobiomics) could improve treatment stratification strategies in psychiatry. In this systematic review and meta-analysis, we first explored whether psychotropics modify the gut microbiome; second, we investigated whether the gut microbiome affects the efficacy and tolerability of psychotropics.
Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched (November 2022) for longitudinal and cross-sectional studies that investigated the effect of psychotropics on the gut microbiome. The primary outcome was the difference in diversity metrics (alpha and beta) before and after treatment with psychotropics (longitudinal studies) and in medicated compared with unmedicated individuals (cross-sectional studies). Secondary outcomes included the association between gut microbiome and efficacy and tolerability outcomes. Random effect meta-analyses were conducted on alpha diversity metrics, while beta diversity metrics were pooled using distance data extracted from graphs. Summary statistics included standardized mean difference and Higgins I for alpha diversity metrics and F and R values for beta diversity metrics.
Nineteen studies were included in our synthesis; 12 investigated antipsychotics and 7 investigated antidepressants. Results showed significant changes in alpha (4 studies; standard mean difference: 0.12; 95% CI: 0.01-0.23; p = .04; I: 14%) and beta (F = 15.59; R = 0.05; p < .001) diversity metrics following treatment with antipsychotics and antidepressants, respectively. Altered gut microbiome composition at baseline was associated with tolerability and efficacy outcomes across studies, including response to antidepressants (2 studies; alpha diversity; standard mean difference: 2.45; 95% CI: 0.50-4.40; p < .001, I: 0%).
Treatment with psychotropic medications is associated with altered gut microbiome composition, and the gut microbiome may in turn influence the efficacy and tolerability of these medications.
了解肠道微生物组与精神药物(精神药理学微生物组学)之间的相互作用,可以改善精神病学中的治疗分层策略。在这项系统评价和荟萃分析中,我们首先探讨了精神药物是否会改变肠道微生物组;其次,我们研究了肠道微生物组是否会影响精神药物的疗效和耐受性。
根据 PRISMA(系统评价和荟萃分析的首选报告项目)指南,我们检索了(2022 年 11 月)调查精神药物对肠道微生物组影响的纵向和横断面研究。主要结局是治疗前后(纵向研究)和用药与未用药个体之间(横断面研究)的多样性指标(α和β)的差异。次要结局包括肠道微生物组与疗效和耐受性结局的相关性。对 α多样性指标进行随机效应荟萃分析,对β多样性指标则使用从图表中提取的距离数据进行汇总。汇总统计数据包括α多样性指标的标准化均数差和 Higgins I,以及β多样性指标的 F 和 R 值。
19 项研究纳入我们的综述;其中 12 项研究抗精神病药,7 项研究抗抑郁药。结果显示,抗精神病药和抗抑郁药治疗后α(4 项研究;标准化均数差:0.12;95%置信区间:0.01-0.23;p =.04;I:14%)和β(F = 15.59;R = 0.05;p <.001)多样性指标均有显著变化。在各研究中,基线时肠道微生物组组成的改变与耐受性和疗效结局相关,包括对抗抑郁药的反应(2 项研究;α多样性;标准化均数差:2.45;95%置信区间:0.50-4.40;p <.001,I:0%)。
精神药物治疗与肠道微生物组组成的改变有关,而肠道微生物组反过来可能影响这些药物的疗效和耐受性。